Evidence map›Paper›PMID 28554908›Full record

Trial reportJournal of the American Heart Association2017

Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.

Emil Wolsk, Brian Claggett, Marc A Pfeffer, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Francesca C Lawson, Eldrin F Lewis, Aldo P Maggioni, John J V McMurray and 5 more

Registry-linked trialOpen access · goldAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01147250 (A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome), which is not on this map. Cited by 45 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 3 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01147250 phase3completednot on this map

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome

TypeinterventionalSponsorSanofiRan2010 to 2015Enrolled6,068ConditionsAcute Coronary SyndromeArmsLixisenatide (AVE0010), Placebo
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 120 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Navigating the challenges of NT-proBNP result disclosure in clinical research.Journal of clinical and translational science · 2025
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Effect of body mass index on N-terminal pro-brain natriuretic peptide values in patients with heart failure.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2023
    Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 7 countries.

Emil WolskDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Brian ClaggettDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Marc A PfefferDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Rafael DiazEstudios Clínicos Latinoamérica, Rosario, Argentina.
Kenneth DicksteinUniversity of Bergen Stavanger University Hospital, Stavanger, Norway.
Hertzel C GersteinDivision of Endocrinology & Metabolism, McMaster University, Hamilton, Ontario, Canada.
Francesca C LawsonSanofi U.S., Bridgewater, NJ.
Eldrin F LewisDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Aldo P MaggioniResearch Center of the Italian Association of Hospital Cardiologists, Florence, Italy.
John J V McMurrayBritish Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom.
Jeffrey L ProbstfieldDivision of Cardiology, University of Washington Medical Center, Seattle, WA.
Matthew C RiddleDivision of Endocrinology, Oregon Health and Science University, Portland, OR.
Scott D SolomonDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Jean-Claude TardifMontreal Heart Institute, Université de Montréal, Montreal, Canada.
Lars KøberDepartment of Cardiology, Rigshospitalet, Copenhagen, Denmark lars.koeber@regionh.dk.
Harvard University · USBrigham and Women's Hospital · USAssociazione Nazionale Medici Cardiologi Ospedalieri · ITBritish Heart Foundation · GBEstudios Clínicos Latinoamérica · ARMcMaster University · CAMontreal Heart Institute · CAOregon Health & Science University · USRigshospitalet · DKSanofi (United States) · USStavanger University Hospital · NOUniversity of Washington Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNatriuretic peptides are recognized as important predictors of cardiovascular events in patients with heart failure, but less is known about their prognostic importance in patients with acute coronary syndrome. We sought to determine whether B-type natriuretic peptide (BNP) and N-terminal prohormone B-type natriuretic peptide (NT-proBNP) could enhance risk prediction of a broad range of cardiovascular outcomes in patients with acute coronary syndrome and type 2 diabetes mellitus. METHODS AND

resultsPatients with a recent acute coronary syndrome and type 2 diabetes mellitus were prospectively enrolled in the ELIXA trial (n=5525, follow-up time 26 months). Best risk models were constructed from relevant baseline variables with and without BNP/NT-proBNP. C statistics, Net Reclassification Index, and Integrated Discrimination Index were analyzed to estimate the value of adding BNP or NT-proBNP to best risk models. Overall, BNP and NT-proBNP were the most important predictors of all outcomes examined, irrespective of history of heart failure or any prior cardiovascular disease. BNP significantly improved C statistics when added to risk models for each outcome examined, the strongest increments being in death (0.77-0.82,

conclusionsIn patients with a recent acute coronary syndrome and type 2 diabetes mellitus, BNP and NT-proBNP were powerful predictors of cardiovascular outcomes beyond heart failure and death, ie, were also predictive of MI and stroke. Natriuretic peptides added as much predictive information about death as all other conventional variables combined. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT01147250.

Indexed as

Acute Coronary SyndromeAgedBiomarkersCause of DeathDiabetes Mellitus, Type 2FemaleHeart FailureHumansMaleMiddle AgedMyocardial InfarctionNatriuretic Peptide, BrainPeptide FragmentsPredictive Value of TestsPrognosisProspective StudiesBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)acute coronary syndromebiomarkerbrain natriuretic peptidecardiac outcomesdiabetes mellitusEvaluation of Lixisenatide in Acute Coronary Syndrome trialglucagon‐like peptide‐1natriuretic peptideN‐terminal prohormone B‐type natriuretic peptiderisk model

Identifiers

PMID28554908
PMCPMC5669146
OpenAlexW2618557766

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.